Tickers

1. Composite Trajectory Verdict

Given Axon's hybrid hardware/software model with multi-year subscription contracts, the income statement and cash flow statement carry the most weight for assessing operational trajectory, while the balance sheet reflects financing-driven liquidity shifts.

Composite Trajectory: Mixed

Revenue growth remains robust at 33-35% YoY across both annual and recent semi-annual periods (10-K 2025, Consolidated Statements of Operations; 10-Q 2026-06-30, MD&A). However, GAAP operating profitability deteriorated sharply in FY2025, swinging from $58.5M income to a $62.1M loss despite revenue growth, driven by a 66% surge in stock-based compensation to $634.2M (10-K 2025, Consolidated Statements of Operations; Note 14). Quarterly trends reversed in H1 2026, with operating income improving to $76.0M from a $9.8M loss in H1 2025 (10-Q 2026-06-30, MD&A). Operating cash flow declined 48% in FY2025 to $211M and remained negative in H1 2026 (-$11.4M), while the balance sheet shows a 166% debt increase to $1.81B funded by Senior Notes issuance, partially deployed for the $625M Carbyne acquisition (10-K 2025, Consolidated Balance Sheets; 10-Q 2026-06-30, Cash Flows).

2. Red Flags

• GAAP operating income collapse despite 33.5% revenue growth: FY2025 operating loss of $62.1M vs $58.5M income in FY2024 (10-K 2025, Consolidated Statements of Operations)
• Stock-based compensation consuming 22.8% of FY2025 revenue: $634.2M in FY2025 vs $382.6M in FY2024 vs $131.4M in FY2023 (10-K 2025, Consolidated Statements of Cash Flows; Note 14)
• Operating cash flow down 48% YoY in FY2025: $211.3M vs $408.3M in FY2024, with H1 2026 still negative at -$11.4M (10-K 2025, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Cash Flows)
• GAAP-to-adjusted EBITDA gap widening: FY2025 net income $124.7M vs adjusted EBITDA $710.2M (10-K 2025, Non-GAAP Measures reconciliation)
• Effective tax rate extreme volatility: -557.0% in FY2025, 1.2% in FY2024, -11.9% in FY2023 (10-K 2025, Provision for Income Taxes)
• Material weakness in internal controls over revenue recognition identified by auditor (10-K 2025, Report of Independent Registered Public Accounting Firm)
• Cash and investments down 61% in H1 2026: $673.4M at June 30, 2026 vs $1,706.6M at Dec 31, 2025, driven by $551.6M Carbyne acquisition (10-Q 2026-06-30, Liquidity and Capital Resources; Cash Flows)
• Total debt up 166% in FY2025: $1.81B at Dec 31, 2025 vs $680.3M at Dec 31, 2024 (10-K 2025, Consolidated Balance Sheets; Note 10)
• Recurring "non-recurring" severance costs: $31.8M in Q4 2025, $2.7M in H1 2026 (10-K 2025, SG&A Expenses; 10-Q 2026-06-30, Non-GAAP Measures)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

On an annual basis, GAAP operating profitability has deteriorated sharply: operating income fell from $156.9M (FY2023) to $58.5M (FY2024) to a $62.1M loss (FY2025), while net income dropped from $377.0M to $124.7M over the same span despite revenue growing from $2.08B to $2.78B (10-K 2025, Consolidated Statements of Operations). Gross margin percentage was nearly flat at 59.7% vs 59.6%, but total operating expenses rose 45.4% to $1.72B, driven by SG&A (+39.8% to $1.04B) and R&D (+55.0% to $684.3M), both inflated by stock-based compensation (10-K 2025, Consolidated Statements of Operations; MD&A). The H1 2026 semi-annual period shows a reversal to $76.0M operating income from a $9.8M loss in H1 2025, with net income rising to $198.7M from $124.1M (10-Q 2026-06-30, MD&A), but this quarterly improvement does not offset the full-year GAAP deterioration captured in the three-year annual trend.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Annual operating cash flow peaked at $408.3M in FY2024 then fell 48% to $211.3M in FY2025, despite revenue growing 33.5% (10-K 2025, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less capex) declined from $329.5M in FY2024 to $75.1M in FY2025 (capex $136.3M vs $78.8M) (10-K 2025, Consolidated Statements of Cash Flows; Note 5). The H1 2026 period shows operating cash flow of -$11.4M, an improvement from -$65.9M in H1 2025, but remains negative (10-Q 2026-06-30, Cash Flows). Large investing outflows persisted: $724.9M in FY2025 (including $646.9M for business combinations) and $465.8M in H1 2026 (including $551.6M for Carbyne) (10-K 2025, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Cash Flows). Financing inflows of $1.25B in FY2025 from debt and ATM equity masked operating cash weakness, but H1 2026 financing was -$122.6M with no new issuance.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Liquidity increased significantly in FY2025: cash and equivalents rose 164% to $1.20B, and total current assets grew 62% to $3.71B (10-K 2025, Consolidated Balance Sheets). However, this was funded primarily by $1.75B of new Senior Notes (2030/2033), driving total debt up 166% to $1.81B and total liabilities up 75% to $3.76B (10-K 2025, Consolidated Balance Sheets; Note 10). Stockholders' equity grew 39% to $3.24B, boosted by $489.4M ATM proceeds and stock comp APIC additions (10-K 2025, Consolidated Statements of Stockholders' Equity). By June 30, 2026, cash and investments had fallen 61% to $673.4M after the Carbyne acquisition, while the 2027 Notes were fully redeemed/converted (10-Q 2026-06-30, Liquidity and Capital Resources; Note 20). Contract assets grew 56% to $760.9M and remaining performance obligations reached $9.9B, indicating strong revenue visibility (10-K 2025, Note 2). Net leverage ratio per the credit agreement was 0.15x at Dec 31, 2025 (10-K 2025, Note 13).

6. Data Gaps

• Standalone Q3 2025 and Q4 2025 quarterly income statements and cash flows (only FY2025 annual and H1 2026 semi-annual provided)
• Q1 2026 quarterly results (only referenced in H1 2026 10-Q, not provided as separate filing)
• FY2026 full-year guidance or outlook figures (not in provided filings)
• Segment-level operating expenses (R&D, SG&A) for quarterly periods (only annual segment adjusted gross margin provided)
• Detailed breakdown of "Other SG&A expenses" and "Other R&D expenses" for quarterly periods
• Quarterly free cash flow figures prior to H1 2025 (only annual provided in 10-K)
• Post-Carbyne acquisition purchase price allocation details (noted as incomplete in 10-Q 2026-06-30, Note 20)